Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 1, 2003, Pages 53-60

  Kushiya, Fumihiko ^a   Wada, Hideo ^a   Sakakura, Miho ^a   Mori, Yoshitaka ^b   Gabazza, Esteban C ^a   Nishikawa, Masakatsu ^a   Nobori, Tsutomu ^a   Noguchi, Mitsuya ^c   Izumi, Kazuo ^c   Shiku, Hirosi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mie Red Cross Blood Center   (Japan)

^c Matsusaka Chuou Hospital   (Japan)

Author keywords

Atherosclerosis; Coagulation; Hemodialysis; Hemostatic marker

Indexed keywords

ANTITHROMBIN; D DIMER; FIBRIN; FIBRINOGEN; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANKLE; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CAUSE OF DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCORING SYSTEM;

EID: 0037220101     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900107     Document Type: Article

References (33)

1. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of December 31, 1997). J Jpn Social Dial Ther 1999;32:1.
2. United States Renal Data System 1999 Annual Data Report, 73.
3. Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 Diabetes Care 1978;1:168-177, 252-261.
4. Irish A. Cardiovascular disease, fibrinogen and the acutephase response: Association with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133.
5. Nakamura Y, Tomomura S, Tachibana K, et al. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992;38:90.
6. Takagi M, Wada H, Mukai K, et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance hemodialysis. Blood Coagul Fibrinolysis 1994;5:713.
7. Siegel JE, Weinstein MC, Russel LB, et al. Recommendation for reporting cost-effectiveness analyses. For the panel cost effectiveness in health and medicine. JAMA 1996;276:1339.
8. Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270(4):465.
9. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham study. J Am Geriatr Soc 1985;33(1):13.
10. Fishbone S, Youn S, Flaster E, et al. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 1996;27(5):668.
11. Kimura K, Saika Y, Otani H, et al. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl 1999;71:S238.
12. Deguchi K, Izumi K, Noguchi M, et al. Response of the cubital vein to occlusion and calcification of the abdominal aorta in patients with chronic renal failure on maintenance hemodialysis. Thromb Res 1988;49(1):69.
13. Watanabe R, Wada H, Miura Y, et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-I complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2001;7(3):229.
14. Okugawa Y, Wada H, Noda T, et al. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. Am J Hematol 2000;65(3):210.
15. Mori Y, Wada H, Okugawa Y, et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost 2001;7(1):5.
16. Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzymelinked immunosorbent assay. Thromb Hemost 1987;59:101.
17. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985;66(1):59.
18. Mimuro J, Koike Y, Sumi Y, et al. Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. Blood 1987;69(2):446.
19. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioseler Thromb Vasc Biol 1999;19(3):538.
20. Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Atheroselerosis 1997;131(1):115.
21. Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988;17(2):248.
22. Chaudhry H, Holland A, Dormandy J. Comparison of graded versus constant treadmill test protocols for quantifying intermittent claudication. Vasc Med 1997;2(2):93.
23. Bommer J, Strohbeck E, Goerich J, et al. Arteriosclerosis in dialysis patients. Int J Artif Organs 1996;19(11):638.
24. Burdick L, Periti M, Salvaggio A, et al. Relation between carotid artery atherosclerosis and time on dialysis. A noninvasive study in vivo. Clin Nephrol 1994;42(2):121.
25. Kabaya T, Nitta K, Kimura H, et al. Increased aortic calcification index in hemodialysis patients. Nephron 1999;81(3):354.
26. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: Does it exist? Br J Haematol 1995;90(2):244.
27. Blann AD, Dobrotova M, Kubisz P, et al. von Willebrand factor, soluble P-selectin, tissue plasminogen activator, and plasminogen activator inhibitor in atherosclerosis. Thromb Hemost 1995;74(2):626.
28. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Hemost 1994;72(1):151.
29. Speiser W, Speiser P, Minar E, et al. Activaticn of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localization of vessel disease and risk factors. Thromb Res 1990;59(1):77.
30. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341(8854):1165.
31. Hoshino M, Haraguchi Y, Hirasawa H, et al. Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas. Crit Care 2001;5(2):88.
32. Bunker P, Schick A, Pedro T, et al. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. Neurol Res 1999;21(8):727.
33. Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997;46(1):36.